Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Vienna, Austria, 2 September 2007:
Drugs that block a hormonal cascade, known as the renin-angiotensin-aldosterone system (RAAS), help patients with heart failure. Direct renin inhibitors (DRIs) block the RAAS at its first and rate-limiting step. As a result, all downstream products in the RAAS cascade are suppressed and DRIs are specific for the RAAS. Both these properties differentiate DRIs from angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs).
We examined the tolerability and safety of the first clinically available orally acting DRI, aliskiren, in a randomised placebo-controlled trial in heart failure. In the ALiskiren Observation of heart Failure Treatment study (ALOFT) we enrolled 302 patients with New York Heart Association (NYHA) class II-IV heart failure with current or prior hypertension and a plasma B-type natriuretic peptide (BNP) concentration > 100 pg/mL from 73 sites in 9 countries. Patients had to be optimally treated with an ACE-I or ARB and a beta-blocker, unless contraindicated or not tolerated. Patients were studied for 3 months.
Although primarily a safety and tolerability study, a variety of “efficacy” measurements were made. The first three of these were to study the effect of aliskiren, compared to placebo, on N terminal pro BNP, BNP and aldosterone. Compared to placebo, aliskiren reduced plasma NT-pro BNP by 25 (95%CI 6-39)%, p=0.0106; plasma BNP by 25 (5-41)%, p=0.0160 and urinary aldosterone by 21(4-34)%, p=0.0150. There was also a favourable change in a Doppler-echocardiographic measure of left ventricular filling pressure. Aliskiren was well tolerated and there was no significant excess of hypotension or renal dysfunction.
In summary, this first sizeable, placebo-controlled, trial with aliskiren, the lead agent in the new class of orally active DRIs showed favourable neurohumoral and other effects in otherwise optimally treated patients with heart failure. These promising initial findings support further evaluation of aliskiren as a possible future treatment for heart failure.
This study was presented at the ESC Congress 2007 in Vienna.
© 2017 European Society of Cardiology. All rights reserved